This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chaves, F. J. Articles by Carmena, R. Search for Related Content PubMed PubMed Citation Articles by Chaves, F. J. Articles by Carmena, R.

Genetic Diagnosis of Familial Hypercholesterolemia in a South European Outbreed Population: Influence of Low-Density Lipoprotein (LDL) Receptor Gene Mutations on Treatment Response to Simvastatin in Total, LDL, and High-Density Lipoprotein Cholesterol

Institute of Cytological Research (F.J.C., A.B.G.-G., M.E.A.) and Service of Endocrinology and Nutrition (J.T.R., M.C., J.F.A., R.C.), Hospital Clínico Universitario, Department of Medicine, University of Valencia, Valencia, Spain E-46010

Address all correspondence and requests for reprints to: Dr. Rafael Carmena, Department of Medicine, Hospital Clínico Universitario, Avda. Blasco Ibáñez 17, E-46010 Valencia, Spain. E-mail: carmena{at}uv.es

Abstract

The aims of this study were to examine the presence of mutations in the low-density lipoprotein receptor gene among subjects clinically diagnosed with familial hypercholesterolemia and to analyze whether the molecular diagnosis helps to predict the response to simvastatin treatment in our familial hypercholesterolemia population. Fifty-five probands and 128 related subjects with familial hypercholesterolemia were studied. Genetic diagnosis was carried out following a three-step protocol based on Southern blot and PCR-single strand conformational polymorphism analysis. A randomized clinical trial with simvastatin was conducted in 42 genetically diagnosed subjects with familial hypercholesterolemia classified as carriers of null mutations (n = 22) and of defective mutations (n = 20). A mutation-causing familial hypercholesterolemia was identified in 46 probands (84%). In 41 of them (89%), a total of 28 point mutations were detected, 13 of which have not been previously described. The remaining five probands (11%) were carriers of large rearrangements. Familial hypercholesterolemia with null mutations showed a poor response to simvastatin treatment. The mean percentage reduction of plasma total and low-density lipoprotein cholesterol levels in these subjects were significantly lower (24.8 ± 10.3 vs. 34.8 ± 10.9, P = 0.04 and 30.0 ± 39.8 vs. 46.1 ± 18.2, P = 0.02, respectively) than in subjects with defective mutations. Baseline and posttreatment high-density lipoprotein cholesterol plasma values were significantly lower in subjects with familial hypercholesterolemia with null mutations (P < 0.001). In an outbreed Caucasian population, a three-step protocol for genetic screening detected a mutation in the low-density lipoprotein receptor gene in a high percentage (84%) of subjects with familial hypercholesterolemia. Subjects with familial hypercholesterolemia with null mutations (class I) showed lower plasma high-density lipoprotein cholesterol values and a poor low-density lipoprotein cholesterol response to simvastatin treatment.

This article has been cited by other articles:

				O. W. Souverein, J. C. Defesche, A. H. Zwinderman, J. J.P. Kastelein, and M. W.T. Tanck Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolaemia Eur. Heart J., February 1, 2007; 28(3): 299 - 304. [Abstract] [Full Text] [PDF]

				D. S. Christidis, E. N. Liberopoulos, A. I. Kakafika, G. A. Miltiadous, M. Cariolou, E. S. Ganotakis, D. P. Mikhailidis, and M. S. Elisaf The effect of apolipoprotein e polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2006; 11(3): 211 - 221. [Abstract] [PDF]

				S. Blesa, A. B. Garcia-Garcia, S. Martinez-Hervas, M. L. Mansego, V. Gonzalez-Albert, J. F. Ascaso, R. Carmena, J. T. Real, and F. J. Chaves Analysis of Sequence Variations in the LDL Receptor Gene in Spain: General Gene Screening or Search for Specific Alterations? Clin. Chem., June 1, 2006; 52(6): 1021 - 1025. [Abstract] [Full Text] [PDF]

				K. C.M.C. Koeijvoets, J. Rodenburg, B. A. Hutten, A. Wiegman, J. J.P. Kastelein, and E. J.G. Sijbrands Low-Density Lipoprotein Receptor Genotype and Response to Pravastatin in Children With Familial Hypercholesterolemia: Substudy of an Intima-Media Thickness Trial Circulation, November 15, 2005; 112(20): 3168 - 3173. [Abstract] [Full Text] [PDF]

				D. Tejedor, S. Castillo, P. Mozas, E. Jimenez, M. Lopez, M. T. Tejedor, M. Artieda, R. Alonso, P. Mata, L. Simon, et al. Reliable Low-Density DNA Array Based on Allele-Specific Probes for Detection of 118 Mutations Causing Familial Hypercholesterolemia Clin. Chem., July 1, 2005; 51(7): 1137 - 1144. [Abstract] [Full Text] [PDF]

				R.R. Huxley, M.H. Hawkins, S.E. Humphries, F. Karpe, H.A.W. Neil, and J. F. Meschia Risk of Fatal Stroke in Patients With Treated Familial Hypercholesterolemia: A Prospective Registry Study * Editorial Comment Stroke, January 1, 2003; 34(1): 22 - 25. [Abstract] [Full Text] [PDF]